| Аудиторские |  Игры |  Промышленность |  Торговля |  Нефтеные |  Строительство |  Трейдеры |  Инвестиционные |  Юридические |  Оффшорные |  Автомобили |  Страхование |  Комуникации |  Химические компании |  Программы | 
 
Sanofi-Aventis ADS (NYSE: SNY)

Price and Chart delayed at least 15 mintues.
Price $ 29.70 Change 0.00
Open 0.00 % Change 0.0%
Prev Close 29.70 Volume 800
Market Value 78 bil P/E Ratio 13.2
Bid 29.66 EPS 2.25
Ask 29.70 Dividend 1.06
High 0.00 Yield 3.6
Low 0.00 Shares Out 2.63 bil
52wk High 37.11 52wk Low 23.95
Industry: Drug Manufacturers - Major
Sector: Healthcare

SNY Profile

A global pharmaceutical group, which is engaged in the research, development, manufacture and marketing of healthcare products.

Sanofi-Aventis ADS
174 Avenue de France
Paris, 75013
Phone: 01133153774545
Fax: 01133153774303
Web Site: www.sanofi-aventis.com

SNY Wires Headlines

03:38 AM  Sanofi says diabetes drug not riskier than insulin
07.02.09  Sanofi-Aventis arrhythmia drug Multaq approved
07.01.09  FDA reviewing safety of Sanofi's Lantus insulin
06.30.09  Sanofi-Aventis to close some plants, restructure
06.29.09  Study in mice sheds light on Ambien side effects

More SNY From Wires Headlines >

Forbes.com on SNY     RSS

  • Novartis Speeds Ahead On Swine Flu Vaccine
    • The Swiss drugmaker says it will have a vaccine ready by this fall.

    SNY Press Releases

    07.02.09  FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
    06.25.09  Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply
    06.06.09  New Pooled Analysis Found Lantus(R) Reduced A1C and FBG Levels in Adults Over 65 with Type 2...
    06.06.09  New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar

    More SNY Press Releases >

    SNY Ratios & Returns

    Price-to-sales 1.95
    Return on Equity 9.6
    Operating Margin 41.2
    Profit Margin 14.9%

    More SNY Ratios & Returns >

    SNY Financials

    Sales $40.056992 bil
    Profits $5.966083 bil
    Assets $100.065332 bil
    Employees 98213.0
Sanofi-aventis is ranked # 65 on the 2009 Forbes 2000 List
Thomson / IBES Earnings Estimates on SNY
Accounting Risk
Buy/Hold/Sell Analysis
Forbes Investment Guru Commentary on SNY
RSS News Feed on SNY   

A D V E R T I S E M E N T
СМОТРЕТЬ
презентацию